Tiaa Fsb increased its stake in Eli Lilly And Co (NYSE:LLY) by 8.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 105,117 shares of the company’s stock after purchasing an additional 8,028 shares during the period. Tiaa Fsb’s holdings in Eli Lilly And Co were worth $11,755,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of LLY. Nuveen Asset Management LLC increased its position in shares of Eli Lilly And Co by 20,030.9% in the second quarter. Nuveen Asset Management LLC now owns 7,265,844 shares of the company’s stock worth $804,983,000 after purchasing an additional 7,229,751 shares during the period. Renaissance Technologies LLC boosted its stake in Eli Lilly And Co by 218.6% in the second quarter. Renaissance Technologies LLC now owns 2,308,601 shares of the company’s stock valued at $255,770,000 after buying an additional 1,583,947 shares in the last quarter. Grantham Mayo Van Otterloo & Co. LLC boosted its stake in Eli Lilly And Co by 5,612.3% in the second quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 1,591,396 shares of the company’s stock valued at $176,311,000 after buying an additional 1,563,537 shares in the last quarter. AQR Capital Management LLC boosted its stake in Eli Lilly And Co by 53.3% in the second quarter. AQR Capital Management LLC now owns 4,335,702 shares of the company’s stock valued at $480,048,000 after buying an additional 1,507,050 shares in the last quarter. Finally, BlackRock Inc. boosted its stake in Eli Lilly And Co by 1.5% in the second quarter. BlackRock Inc. now owns 61,979,145 shares of the company’s stock valued at $6,866,670,000 after buying an additional 898,845 shares in the last quarter. Institutional investors own 76.72% of the company’s stock.

In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of Eli Lilly And Co stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $116.37, for a total transaction of $24,437,700.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Alfonso G. Zulueta sold 19,500 shares of Eli Lilly And Co stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $112.91, for a total value of $2,201,745.00. Following the sale, the senior vice president now directly owns 38,306 shares in the company, valued at $4,325,130.46. The disclosure for this sale can be found here. Insiders have sold 243,452 shares of company stock worth $28,252,925 over the last three months. Insiders own 0.11% of the company’s stock.

Several analysts recently weighed in on LLY shares. ValuEngine lowered Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Friday, June 28th. Bank of America set a $120.00 price objective on Eli Lilly And Co and gave the company a “neutral” rating in a research note on Tuesday, September 10th. Nine analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Eli Lilly And Co has an average rating of “Hold” and a consensus price target of $122.92.

NYSE:LLY traded down $0.08 during trading hours on Wednesday, hitting $107.11. The company’s stock had a trading volume of 12,382 shares, compared to its average volume of 8,205,623. The stock has a fifty day simple moving average of $111.75 and a 200-day simple moving average of $115.06. The company has a market capitalization of $104.46 billion, a P/E ratio of 19.30, a PEG ratio of 1.87 and a beta of 0.16. The company has a debt-to-equity ratio of 4.98, a current ratio of 1.13 and a quick ratio of 0.87. Eli Lilly And Co has a twelve month low of $104.17 and a twelve month high of $132.13.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Tuesday, July 30th. The company reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.45 by $0.05. Eli Lilly And Co had a return on equity of 70.86% and a net margin of 33.76%. The business had revenue of $5.64 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period last year, the firm posted $1.48 earnings per share. Eli Lilly And Co’s revenue was up .9% compared to the same quarter last year. On average, equities analysts predict that Eli Lilly And Co will post 5.73 EPS for the current fiscal year.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: What is the Beige Book?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.